Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,114.71
    +35.85 (+0.44%)
     

  • Bitcoin USD

    64,419.12
    +626.62 (+0.98%)
     

  • CMC Crypto 200

    1,391.67
    -4.86 (-0.35%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,361.10
    +18.60 (+0.79%)
     

  • Crude Oil

    83.91
    +0.34 (+0.41%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Company News for June 2, 2020

Zacks Equity Research
·1-min read

  • Shares of Myovant Sciences Ltd. MYOV jumped 38.2% after the company submitted New Drug Application to the FDA for treatment of women with uterine fibroids.

  • Shares of Iterum Therapeutics plc ITRM plunged 59.6% after the company reported topline results for a Phase 3 clinical trial of oral and IV sulopenem in complicated urinary tract infection.

  • Shares of Coty Inc. COTY soared 20.9% after the company announced that KKR plans to acquire 60% of Coty's professional and retail hair business for $2.5 billion as a part of strategic transformation.

  • Shares of OPKO Health, Inc. OPK rose 6.1% after the company reported that it was authorized by the FDA for a trial evaluating RAYALDEE in coronavirus patients.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
 
Coty Inc. (COTY) : Free Stock Analysis Report
 
Myovant Sciences Ltd. (MYOV) : Free Stock Analysis Report
 
Iterum Therapeutics PLC (ITRM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.